Duloxetine DR Capsules USP 60 mg recall — Class II (D-0107-2025) · pharmaranks
Class IIOngoing
Duloxetine DR Capsules USP 60 mg recall
FDA recall D-0107-2025 · initiated Nov 19, 2024
May cause temporary or medically reversible harm; low probability of serious harm.
Why it was recalled
CGMP Deviations: Presence of N-nitroso-duloxetine impurity above recommended interim limit
Details
Product
Duloxetine DR Capsules USP 60 mg, a) 30 count (NDC 57237-019-30), b) 90 count NDC 57237-019-90 and c) 1000 count (NDC 57237-019-99) bottles, Distributed by: Rising Pharmaceuticals, Inc., East Brunswick, NJ
Recalling company
Rising Pharma Holding, Inc.
Classification
Class II
Status
Ongoing
Type
Voluntary: Firm initiated
Distribution
Nationwide.
Initiated
Nov 19, 2024
FDA report date
Dec 11, 2024
What to do.If you have a recalled product, don't throw away questions — check the FDA notice for the affected lot numbers and expiration dates, and ask your pharmacist or doctor before stopping a prescribed medicine. This page reproduces public FDA data and is not medical advice.